Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion

American Journal of Health-System Pharmacy

Volumn 57, Issue 11, 2000, Pages 1046-1050

  Vandenberg, Chad M ^b,c   Kazmi, Yusuf ^d   Stewart, James ^e   Weidler, Donald J ^f   Tenjarla, Srini N ^a   Ward, Earl S ^f   Jann, Michael W ^c  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b Somerset Pharmaceuticals   (United States)

^c MERCER UNIVERSITY   (United States)

^d Solvay Pharmaceuticals Inc   (Netherlands)

^e UNIVERSITY OF GEORGIA   (United States)

^f Mercer Univ S School of Pharmacy ^*

Author keywords

Absorption; Blood levels; Compounding; Dosage forms; Drugs, availability; Equivalency; Gastrointestinal drugs; Injections; Ondansetron hydrochloride; Pharmacokinetics; Suppositories; Tablets

Indexed keywords

ONDANSETRON;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG FORMULATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SUPPOSITORY; TABLET;

EID: 0342656572     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.11.1046     Document Type: Article

References (12)

1. Wilde MI, Markham A. Ondansetron. Drugs. 1996; 52:773-94.
2. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995; 29:95-109.
3. Simpson KH, Hicks FM. Clinical pharmacokinetics of ondansetron: a review. J Pharm Pharmacol. 1996; 48:774-81.
4. Jann MW, ZumBrunnen TL, Tenjarla SN et al. Relative bioavailability of ondansetron 8 mg oral tablets versus two extemporaneous 160-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998; 18:288-94.
5. Hsyu PH, Pritchard JF, Bozigian HP et al. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon and to the rectum. Pharm Res. 1994; 11:156-9.
6. Bozigian HP, Pritchard JF, Gooding AE et al. Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci. 1994; 83:1011-3.
7. DeWit R, Beijnen JH, Van Tellingen O et al. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. Br J Cancer. 1996; 74:323-6.
8. Tenjarla SN, Ward ES, Fox JL. Ondansetron suppositories: extemporaneous preparation, drug release, stability and flux through rabbit rectal membrane. Int J Pharm Compounding. 1998; 2:83-8.
9. Colthup PV, Felgate CC, Palmer JL et al. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J Pharm Sci. 1991; 80:868-71.
10. Pritchard JF, Bryson JC, Kernodle AE et al. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992; 51:51-5.
11. Dixon CM, Colthup PV, Serabjit-Singh CJ et al. Multiple forms of cytochrome P 450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995; 23:1225-30.
12. Zofran package insert. Research Triangle Park, NC: Glaxo Wellcome, Inc. 1996 Oct.